Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Prior approval opinions of independent directors
As an independent director of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) (hereinafter referred to as “the company”), we carefully reviewed the relevant proposals to be submitted to the 20th meeting of the first board of directors of the company for deliberation based on our independent judgment in accordance with the provisions of the articles of association and other relevant laws, regulations and normative documents.
1、 After careful verification, we have carefully reviewed the proposal on foreign investment in private equity funds and related party transactions by wholly owned subsidiaries submitted by the company, and believe that the company’s participation in investment funds and related party transactions this time complies with the provisions of relevant laws, regulations and normative documents. This transaction follows the principle of fair and reasonable market, conforms to the company’s development plan, and does not damage the interests of the company and all shareholders.
In conclusion, we agree to submit the proposal on foreign investment in private equity funds and related party transactions by wholly-owned subsidiaries to the 20th meeting of the first board of directors for deliberation and voting. 2、 Proposal on estimated daily connected transactions of the company in 2022
After careful verification, the daily related party transactions expected to occur in 2022 are the normal business needs of the company, and the relevant transactions follow the principles of consensus and fair transaction. All related party transactions are carried out according to the fair pricing method, and there is no situation that damages the interests of the company and all shareholders. Related party transactions will not have any adverse impact on the company’s financial status and operating results, and the company’s main business will not rely on related parties due to such transactions. In conclusion, we agree to submit the proposal on the expected daily connected transactions of the company in 2022 to the 20th meeting of the first board of directors for deliberation and voting.
(no text below this page)
